Gene Knowledge Graph
UTC
Standard

Serum metabolite levels

NAT2 · rs4921913

Where this position leads

Drug: Hydralazine

rs4921913 Drug: Hydralazine Hydralazine Drug rs4921913 rs4921913 NAT2

What each result means

C/C Published research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Serum metabolite levels compared to the general population. (GWAS Catalog, Am J Hum Genet 2020, PMID:33031748)
C/T Published research associates this genotype (one copy of the reported risk allele) with an intermediate association with Serum metabolite levels. (GWAS Catalog, Am J Hum Genet 2020, PMID:33031748)
T/T Published research associates this genotype with typical/baseline likelihood of Serum metabolite levels — no copies of the reported risk allele. (GWAS Catalog, Am J Hum Genet 2020, PMID:33031748)

Source: GWAS Catalog, Am J Hum Genet 2020, PMID:33031748

Questions about rs4921913

What is rs4921913?

rs4921913 is a single position in the genome, in or near the NAT2 gene. Published research associates it with serum metabolite levels. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

Does rs4921913 affect how medicines work?

NAT2 carries pharmacogenomic findings for Hydralazine. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.

Does having rs4921913 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs4921913 come from?

GWAS Catalog, Am J Hum Genet 2020, PMID:33031748. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

← See all variants